Hanmi Pharmaceutical CEO met Lilly CEO for collaboration
Hanmi Pharmaceutical CEO met Lilly CEO for collaboration
  • by Lee Jae-seung(jasonlee@koreaittimes.com)
  • 승인 2015.04.21 01:39
  • 댓글 0
이 기사를 공유합니다

Chairman Lim Sung-Ki of Hanmi Pharmaceutical(Right) gave a welcome CEO. John C. Lechleiter of Eli Lilly and Company on Hanmi Pharmaceutical Headquarter in Seoul

Chairman Lim Sung-Ki of Hanmi Pharmaceutical((www.hanmipharm.com) met CEO. John C. Lechleiter of Eli Lilly and Company(www.lilly.com).

Two Chief Executive Officers of both companies met Hanmi Pharmaceutical Headquarter in Songpa-Gu, Seoul on on April 19. Additionally President Lee Gwan-sun President of Hanmi Pharmaceutical and President Paul Henry Huibers of Korea Lilly Company attended.

On last March 19, Hanmi Pharmaceutical and Eli Lilly and Company announced they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.

By Lee Jae-seung

댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • Korea IT Times: Copyright(C) 2004, Korea IT Times. .Allrights reserved.
  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • * Mobile News: m.koreaittimes.com
  • * Internet news: www.koreaittimes.com
  • * Editorial Div. 02-578-0434 / 010-2442-9446 * PR Global/AD: 82-2-578-0678.
  • * IT Times Canada: Willow St. Vancouver BC
  • 070-7008-0005
  • * Email: info@koreaittimes.com
ND소프트